Cargando…
Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS
PURPOSE: We aimed at exploring the quality of life (QOL) of lung cancer survivors with proven tyrosine-kinase receptor (RTK) genetic alterations and targeted tyrosine-kinase inhibitors (TKI) therapy, compared to lung cancer survivors with no-RTK alterations and no-TKI therapy. METHODS: Data were col...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293811/ https://www.ncbi.nlm.nih.gov/pubmed/35608689 http://dx.doi.org/10.1007/s00432-022-03975-6 |
_version_ | 1784749717578579968 |
---|---|
author | Riccetti, Nicola Blettner, Maria Taylor, Katherine Wehler, Beatrice Gohrbandt, Bernhard Nestle, Ursula Bals, Robert Stockinger, Marcus Wehler, Thomas Singer, Susanne Eichler, Martin |
author_facet | Riccetti, Nicola Blettner, Maria Taylor, Katherine Wehler, Beatrice Gohrbandt, Bernhard Nestle, Ursula Bals, Robert Stockinger, Marcus Wehler, Thomas Singer, Susanne Eichler, Martin |
author_sort | Riccetti, Nicola |
collection | PubMed |
description | PURPOSE: We aimed at exploring the quality of life (QOL) of lung cancer survivors with proven tyrosine-kinase receptor (RTK) genetic alterations and targeted tyrosine-kinase inhibitors (TKI) therapy, compared to lung cancer survivors with no-RTK alterations and no-TKI therapy. METHODS: Data were collected in a cross-sectional multi-centre study. Primary lung cancer survivors were asked about their socio-demographic and clinical information, QOL, symptom burden, and distress. QOL and symptom burden were assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), and distress with the Patient Health Questionnaire-4 (PHQ-4). Demographic and clinical characteristics were reported in absolute and relative frequencies, QOL, and symptom burden using mean scores. Differences in mean scores with relative 95% confidence intervals were used for comparison. RESULTS: Three groups of survivors were defined: group A with proven RTK alterations, TKI therapy at any time during therapy, and stage IV lung cancer at diagnosis (n = 49); group B: non-TKI therapy and stage IV lung cancer (n = 121); group C: non-TKI therapy and stage I–III lung cancer (n = 495). Survivors in group A reported lower QOL (mean score difference = -11.7 vs. group B) and symptom burden for dyspnoea (difference = -11.5 vs. group C), and higher symptom burden for appetite loss (difference = + 11.4 vs. group C), diarrhoea and rash (differences = + 25.6, + 19.6 and + 13.2, + 13.0, respectively, vs. both groups). CONCLUSIONS: Our results suggest that the specific side effects of TKI therapy can impair QOL among lung cancer survivors. Therefore, specific focus towards the optimal management of these side effects should be considered. |
format | Online Article Text |
id | pubmed-9293811 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-92938112022-07-20 Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS Riccetti, Nicola Blettner, Maria Taylor, Katherine Wehler, Beatrice Gohrbandt, Bernhard Nestle, Ursula Bals, Robert Stockinger, Marcus Wehler, Thomas Singer, Susanne Eichler, Martin J Cancer Res Clin Oncol Original Article – Cancer Research PURPOSE: We aimed at exploring the quality of life (QOL) of lung cancer survivors with proven tyrosine-kinase receptor (RTK) genetic alterations and targeted tyrosine-kinase inhibitors (TKI) therapy, compared to lung cancer survivors with no-RTK alterations and no-TKI therapy. METHODS: Data were collected in a cross-sectional multi-centre study. Primary lung cancer survivors were asked about their socio-demographic and clinical information, QOL, symptom burden, and distress. QOL and symptom burden were assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), and distress with the Patient Health Questionnaire-4 (PHQ-4). Demographic and clinical characteristics were reported in absolute and relative frequencies, QOL, and symptom burden using mean scores. Differences in mean scores with relative 95% confidence intervals were used for comparison. RESULTS: Three groups of survivors were defined: group A with proven RTK alterations, TKI therapy at any time during therapy, and stage IV lung cancer at diagnosis (n = 49); group B: non-TKI therapy and stage IV lung cancer (n = 121); group C: non-TKI therapy and stage I–III lung cancer (n = 495). Survivors in group A reported lower QOL (mean score difference = -11.7 vs. group B) and symptom burden for dyspnoea (difference = -11.5 vs. group C), and higher symptom burden for appetite loss (difference = + 11.4 vs. group C), diarrhoea and rash (differences = + 25.6, + 19.6 and + 13.2, + 13.0, respectively, vs. both groups). CONCLUSIONS: Our results suggest that the specific side effects of TKI therapy can impair QOL among lung cancer survivors. Therefore, specific focus towards the optimal management of these side effects should be considered. Springer Berlin Heidelberg 2022-05-24 2022 /pmc/articles/PMC9293811/ /pubmed/35608689 http://dx.doi.org/10.1007/s00432-022-03975-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article – Cancer Research Riccetti, Nicola Blettner, Maria Taylor, Katherine Wehler, Beatrice Gohrbandt, Bernhard Nestle, Ursula Bals, Robert Stockinger, Marcus Wehler, Thomas Singer, Susanne Eichler, Martin Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS |
title | Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS |
title_full | Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS |
title_fullStr | Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS |
title_full_unstemmed | Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS |
title_short | Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS |
title_sort | quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (tki): results from the multi-centre cross-sectional german study laris |
topic | Original Article – Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293811/ https://www.ncbi.nlm.nih.gov/pubmed/35608689 http://dx.doi.org/10.1007/s00432-022-03975-6 |
work_keys_str_mv | AT riccettinicola qualityoflifeinlungcancersurvivorstreatedwithtyrosinekinaseinhibitorstkiresultsfromthemulticentrecrosssectionalgermanstudylaris AT blettnermaria qualityoflifeinlungcancersurvivorstreatedwithtyrosinekinaseinhibitorstkiresultsfromthemulticentrecrosssectionalgermanstudylaris AT taylorkatherine qualityoflifeinlungcancersurvivorstreatedwithtyrosinekinaseinhibitorstkiresultsfromthemulticentrecrosssectionalgermanstudylaris AT wehlerbeatrice qualityoflifeinlungcancersurvivorstreatedwithtyrosinekinaseinhibitorstkiresultsfromthemulticentrecrosssectionalgermanstudylaris AT gohrbandtbernhard qualityoflifeinlungcancersurvivorstreatedwithtyrosinekinaseinhibitorstkiresultsfromthemulticentrecrosssectionalgermanstudylaris AT nestleursula qualityoflifeinlungcancersurvivorstreatedwithtyrosinekinaseinhibitorstkiresultsfromthemulticentrecrosssectionalgermanstudylaris AT balsrobert qualityoflifeinlungcancersurvivorstreatedwithtyrosinekinaseinhibitorstkiresultsfromthemulticentrecrosssectionalgermanstudylaris AT stockingermarcus qualityoflifeinlungcancersurvivorstreatedwithtyrosinekinaseinhibitorstkiresultsfromthemulticentrecrosssectionalgermanstudylaris AT wehlerthomas qualityoflifeinlungcancersurvivorstreatedwithtyrosinekinaseinhibitorstkiresultsfromthemulticentrecrosssectionalgermanstudylaris AT singersusanne qualityoflifeinlungcancersurvivorstreatedwithtyrosinekinaseinhibitorstkiresultsfromthemulticentrecrosssectionalgermanstudylaris AT eichlermartin qualityoflifeinlungcancersurvivorstreatedwithtyrosinekinaseinhibitorstkiresultsfromthemulticentrecrosssectionalgermanstudylaris |